2022 World Conference on Lung Cancer (ePosters)-EP08.02-089. Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer

EP08.02-089. Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer

Back to course

Pdf Summary

A study was conducted to evaluate the toxicity of sequential treatment with immune checkpoint inhibitors (ICI) followed by targeted therapy in patients with advanced non-small cell lung cancer (NSCLC). The study aimed to characterize and assess the safety signals of this treatment approach in real-world NSCLC patients.<br /><br />The results of the study showed that less than 1% of the patients received ICI upfront, indicating appropriate treatment initiation after the availability of next generation sequencing assay results. In the stage IV NSCLC population, there was no significant safety signal observed with sequential treatment of ICI followed by tyrosine kinase inhibitors (TKIs). Only one patient required treatment break or discontinuation due to pneumonitis.<br /><br />The study differed from existing literature possibly because the majority of the population was treated with first-generation EGFR TKIs and there were limited patients treated with agents associated with safety signals. The study suggests that further research should be conducted to understand the frequency and treatment implications of sequential ICI and targeted therapy.<br /><br />The study included 30 NSCLC patients who received sequential ICI followed by TKI between 2017 and 2021. Among these patients, five experienced immune-related adverse events after ICI only, including pneumonitis, autoimmune hemolytic anemia, adrenal insufficiency, colitis, and stomatitis. One patient had an immune-related adverse event after both ICI and TKI, presenting with pneumonitis. The median onset of ICI toxicity was 4.1 months.<br /><br />The study collected retrospective data on patient demographics, performance status, staging, mutation status, treatment, toxicity, and survival. Significant toxicity resulting in treatment breaks, discontinuation, or initiation of oral steroids was recorded.<br /><br />Overall, the study found that sequential treatment with ICI followed by TKI in NSCLC patients did not result in significant safety signals. However, further studies are needed to gain a better understanding of the frequency and treatment implications of this treatment approach.

Asset Subtitle

Lauren Jones

Meta Tag

Speaker Lauren Jones

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

study

toxicity

ICI

NSCLC

safety signals

TKIs

pneumonitis

EGFR TKIs

immune-related adverse events

retrospective data